文献速递前列腺癌

磁共振成像靶向前列腺穿刺对比系统穿刺:前瞻性随机试验PRECISE的2年随访

Magnetic Resonance Imaging-Targeted Versus Systematic Prostate Biopsies: 2-year Follow-up of a Prospective Randomized Trial (PRECISE).
PubMed 文献 · Eur Urol Oncol · 2023-10-12

PRECISE前瞻性随机试验在5家加拿大中心比较仅靶向穿刺与系统穿刺,2年随访时两组临床显著前列腺癌诊断率无差异,尽管MRI组38%免于初始穿刺、30%完全免于穿刺,但两组2年MRI可评估率仅56%与49%。

要点

  • 2年随访时MRI组与SBx组无GG≥2疾病、治疗、死亡或进展的比例无显著差异(OR 1.08)。
  • MRI组38%免于初始穿刺、30%完全免于穿刺,2年时两组临床显著前列腺癌诊断率无差异。
  • 2年MRI可评估率MRI组56%、SBx组49%,原文未报告局限性。

核心结论

  • 经过包括2年MRI的随访,MRI组与SBx组的临床显著前列腺癌诊断率无差异,即使MRI组38%的男性免于初始穿刺。

研究设计与样本

  • PRECISE前瞻性随机试验在5家加拿大学术中心开展,共453例随机患者,其中146例基线诊断为GG≥2被排除。
  • 本分析纳入MRI组83例MRI阴性未穿刺者、总体队列中120例SBx或TBx阴性者、72例GG1患者。
  • 干预为2年时对MRI组和SBx组所有男性行MRI,对PI-RADS评分≥3或临床怀疑病灶行靶向穿刺。

主要发现

  • MRI组75例(56%)和SBx组69例(49%)有可评估的2年MRI。
  • MRI组55例(73%)和SBx组51例(67%)2年MRI阴性。
  • SBx组76例有2年MRI者中16例(21%)行穿刺,结果阴性8例(10%)、GG1 2例(2.6%)、GG≥2 6例(7.9%)。
  • MRI组75例有2年MRI者中8例(11%)行穿刺,结果阴性4例(5%)、GG≥2 4例(5%)。
  • 2年时包括基线穿刺结果,MRI组116/221(52.5%)和SBx组113/204(55%)无GG≥2疾病、治疗、死亡或进展(OR 1.08;p=0.66)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prospective randomized PRECISE trial demonstrated that magnetic resonance imaging (MRI) with only targeted biopsy (TBx) was noninferior to systematic transrectal ultrasound biopsy (SBx) in the detection of International Society of Urological Pathology grade group (GG) ≥2 prostate cancer (PC). An unanswered question is the outcome for patients who avoided a biopsy because of negative MRI findings. OBJECTIVE: To explore the rate of PC diagnosis based on 2-yr MRI for PRECISE participants who had no biopsy and for patients who had a negative result or GG 1 on TBx in comparison to those with a negative result or GG 1 on SBx. DESIGN, SETTING, AND PARTICIPANTS: The PRECISE prospective trial was conducted at five Canadian academic centers. The present analysis was for trial participants who were not diagnosed with clinically significant PC (csPC) at baseline. Of 453 randomized patients, 146 were diagnosed with GG ≥2 at baseline and were excluded. Eligible patients for this study included 83 men from the MRI arm who had negative MRI findings and no biopsy, 120 from the overall cohort who had a negative SBx or TBx, and 72 from the overall cohort who were diagnosed with GG 1 disease. INTERVENTION: MRI at 2 yr in all men in the MRI and SBx arms and TBx for lesions with a Prostate Imaging-Reporting and Data System score of ≥3 or on the basis of clinical suspicion. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was the proportion of men diagnosed with GG ≥2 cancer. Secondary outcomes included the MRI outcome and the proportion of men diagnosed with GG 1 PC. RESULTS AND LIMITATIONS: Evaluable 2-yr MRI scans were available for 75 (56%) eligible patients in the MRI arm and 69 (49%) in the SBx arm. Of these patients, 55 (73%) in the MRI arm and 51 (67%) SBx arm had negative 2-yr MRI. Of the 76 patients in the SBx arm with 2-yr MRI, 16 (21%) had a biopsy, for which the result was negative in eight (10%), GG1 in two (2.6%), and GG ≥2 in six (7.9%) cases. Of the 75 men in the MRI arm with 2-yr MRI, eight (11%) were biopsied, for which the result was negative in four cases (5%) and GG ≥2 in the other four (5%). At 2 yr, including baseline biopsy results, 116/221 (52.5%) in the MRI arm and 113/204 (55%) in the SBx arm were free of GG ≥2 disease, treatment, death from any cause, or progression (OR 1.08; p = 0.66). CONCLUSIONS: After 2-yr follow-up including MRI for patients in both arms of PRECISE, there was no difference in the rate of csPC diagnosis between the MRI and SBx groups, even though 38% of men in the MRI group avoided an initial biopsy. PATIENT SUMMARY: The PRECISE trial compared systematic biopsy of the prostate to a strategy of magnetic resonance imaging (MRI) with targeted biopsy of any lesions suspicious for cancer on the scan. After 2 years of follow-up that included 2-year MRI with or without biopsy in both groups, there was no difference in the rate of diagnosis of significant cancer, even though 38% of men in the initial MRI arm avoided an initial biopsy, and 30% avoided biopsy altogether. The PRECISE trial is registered on ClinicalTrials.gov as NCT02936258.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Klotz L, Chin J, Black PC, et al. Magnetic Resonance Imaging-Targeted Versus Systematic Prostate Biopsies: 2-year Follow-up of a Prospective Randomized Trial (PRECISE). Eur Urol Oncol. 2023. PMID: 37838556. doi:10.1016/j.euo.2023.09.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。